{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:45:38Z","timestamp":1793403938795,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005224","name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100005224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005224","name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100005224","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Bonn","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Maria Zambrano Fellowship","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-1265840A-100"],"award-info":[{"award-number":["PID2021-1265840A-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"ERDF","doi-asserted-by":"crossref","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008131","name":"University of Bonn","doi-asserted-by":"crossref","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["205167"],"award-info":[{"award-number":["205167"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH UK","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"NIH UK","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"DRI","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Eisei pharmaceuticals","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"US National Institute of Neurological Disorders","award":["nU54,2xR01"],"award-info":[{"award-number":["nU54,2xR01"]}]},{"name":"Chan Zuckerberg Collaborative Pairs Initiative Phase 2","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"UK Dementia Research Institute (DRI), which receives its funding from DRI Ltd., the UK Medical Research Council and Alzheimer\u2019s Society, and Alzheimer\u2019s Research UK."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Synucleinopathies such as Parkinson\u2019s disease (PD) are defined by the accumulation and aggregation of the \u03b1-synuclein protein in neurons, glia and other tissues. We have previously shown that destabilization of \u03b1-synuclein tetramers is associated with familial PD due to\n                    <jats:italic>SNCA<\/jats:italic>\n                    mutations and demonstrated brain-region specific alterations of \u03b1-synuclein multimers in sporadic PD patients following the classical Braak spreading theory. In this study, we assessed relative levels of disordered and higher-ordered multimeric forms of cytosolic \u03b1-synuclein in blood from familial PD with G51D mutations and sporadic PD patients. We used an adapted in vitro-cross-linking protocol for human EDTA-whole blood. The relative levels of higher-ordered \u03b1-synuclein tetramers were diminished in blood from familial PD and sporadic PD patients compared to controls. Interestingly, the relative amount of \u03b1-synuclein tetramers was already decreased in asymptomatic G51D carriers, supporting the hypothesis that \u03b1-synuclein multimer destabilization precedes the development of clinical PD. Our data, therefore suggest that measuring \u03b1-synuclein tetramers in blood may have potential as a facile biomarker assay for early detection and quantitative tracking of PD progression.\n                  <\/jats:p>","DOI":"10.1038\/s44321-024-00083-5","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T11:04:12Z","timestamp":1717585452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson\u2019s patients"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-482X","authenticated-orcid":false,"given":"Laura","family":"de Boni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Hays Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-7132","authenticated-orcid":false,"given":"Alejandro","family":"Ruiz-Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Ann","family":"Leyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bourinaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Hannaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"W\u00fcllner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-0979","authenticated-orcid":false,"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn H","family":"Falkenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5330","authenticated-orcid":false,"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"B\u00e4hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"B\u00fcrger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-7435","authenticated-orcid":false,"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"L\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8237-4481","authenticated-orcid":false,"given":"Bj\u00f6rn-Hendrik","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Spottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Haustein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Houlden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-6325","authenticated-orcid":false,"given":"Rimona S","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-5612","authenticated-orcid":false,"given":"Tim","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"83_CR1","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1007\/s12035-016-0266-8","volume":"54","author":"R Abdullah","year":"2017","unstructured":"Abdullah R, Patil KS, Rosen B, Pal R, Prabhudesai S, Lee S, Basak I, Hoedt E, Yang P, Panick K et al (2017) Subcellular Parkinson\u2019s disease-specific alpha-synuclein species show altered behavior in neurodegeneration. Mol Neurobiol 54:7639\u20137655","journal-title":"Mol Neurobiol"},{"key":"83_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam P, Bousset L, Melki R, Otzen DE (2019) \u03b1-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150:522\u2013534","journal-title":"J Neurochem"},{"key":"83_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/srep30473","volume":"6","author":"K Araki","year":"2016","unstructured":"Araki K, Yagi N, Nakatani R, Sekiguchi H, So M, Yagi H, Ohta N, Nagai Y, Goto Y, Mochizuki H (2016) A small-angle X-ray scattering study of alpha-synuclein from human red blood cells. Sci Rep 6:30473","journal-title":"Sci Rep"},{"key":"83_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/mds.28941","volume":"37","author":"L Barba","year":"2022","unstructured":"Barba L, Paolini Paoletti F, Bellomo G, Gaetani L, Halbgebauer S, Oeckl P, Otto M, Parnetti L (2022) Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers. Mov Disord 37:669\u2013683","journal-title":"Mov Disord"},{"key":"83_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P et al (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5:55\u201359","journal-title":"Neurodegener Dis"},{"key":"83_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ (2011) \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107\u2013110","journal-title":"Nature"},{"key":"83_CR7","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1021\/acs.jpcb.9b02381","volume":"123","author":"G Bellomo","year":"2019","unstructured":"Bellomo G, Bologna S, Cerofolini L, Paciotti S, Gatticchi L, Ravera E, Parnetti L, Fragai M, Luchinat C (2019) Dissecting the interactions between human serum albumin and \u03b1-synuclein: new insights on the factors influencing \u03b1-synuclein aggregation in biological fluids. J Phys Chem B 123:4380\u20134386","journal-title":"J Phys Chem B"},{"key":"83_CR8","doi-asserted-by":"crossref","unstructured":"Bellomo G, Paciotti S, Concha-Marambio L, Rizzo D, Wojda\u019aa AL, Chiasserini D, Gatticchi L, Cerofolini L, Giuntini S, De Luca CMG et al (2023) Cerebrospinal fluid lipoproteins inhibit \u03b1-synuclein aggregation by interacting with oligomeric species in seed amplification assays. Mol Neurodegener 18:20","DOI":"10.1186\/s13024-023-00613-8"},{"key":"83_CR9","doi-asserted-by":"crossref","unstructured":"de Boni L, Watson AH, Zaccagnini L, Wallis A, Zhelcheska K, Kim N, Sanderson J, Jiang H, Martin E, Cantlon A et al (2022) Brain region-specific susceptibility of Lewy body pathology in synucleinopathies is governed by \u03b1-synuclein conformations. Acta Neuropathol 143:453\u2013469","DOI":"10.1007\/s00401-022-02406-7"},{"key":"83_CR10","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3233\/JPD-223516","volume":"12","author":"IC Br\u00e1s","year":"2022","unstructured":"Br\u00e1s IC, Khani MH, Vasili E, M\u00f6bius W, Riedel D, Parfentev I, Gerhardt E, Fahlbusch C, Urlaub H, Zweckstetter M et al (2022) Molecular mechanisms mediating the transfer of disease-associated proteins and effects on neuronal activity. J Parkinsons Dis 12:2397\u20132422","journal-title":"J Parkinsons Dis"},{"key":"83_CR11","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1021\/acs.jproteome.7b00025","volume":"16","author":"AH Bryk","year":"2017","unstructured":"Bryk AH, Wi\u015bniewski JR (2017) Quantitative analysis of human red blood cell proteome. J Proteome Res 16:2752\u20132761","journal-title":"J Proteome Res"},{"key":"83_CR12","doi-asserted-by":"publisher","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","volume":"111","author":"J Burr\u00e9","year":"2014","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC (2014) \u03b1-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA 111:E4274\u201383","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR13","doi-asserted-by":"publisher","first-page":"a024091","DOI":"10.1101\/cshperspect.a024091","volume":"8","author":"J Burr\u00e9","year":"2018","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC (2018) Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb Perspect Med 8:a024091","journal-title":"Cold Spring Harb Perspect Med"},{"key":"83_CR14","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/brain\/awad150","volume":"146","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Di Lazzaro G, Marino G, Campanelli F, Ghiglieri V (2023) Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease. Brain 146:3587\u20133597","journal-title":"Brain"},{"key":"83_CR15","doi-asserted-by":"publisher","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","volume":"95","author":"LM Chahine","year":"2020","unstructured":"Chahine LM, Beach TG, Brumm MC, Adler CH, Coffey CS, Mosovsky S, Caspell-Garcia C, Serrano GE, Munoz DG, White CL et al (2020) In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology 95:e1267\u2013e1284","journal-title":"Neurology"},{"key":"83_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA et al (2012) Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell 149:1048\u20131059","journal-title":"Cell"},{"key":"83_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3233\/JAD-201038","volume":"80","author":"S Daniele","year":"2021","unstructured":"Daniele S, Baldacci F, Piccarducci R, Palermo G, Giampietri L, Manca ML, Pietrobono D, Frosini D, Nicoletti V, Tognoni G et al (2021) \u03b1-Synuclein heteromers in red blood cells of Alzheimer\u2019s disease and Lewy body dementia patients. J Alzheimers Dis 80:885\u2013893","journal-title":"J Alzheimers Dis"},{"key":"83_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.bbapap.2019.05.001","volume":"1867","author":"T Das","year":"2019","unstructured":"Das T, Eliezer D (2019) Membrane interactions of intrinsically disordered proteins: the example of alpha-synuclein. Biochim Biophys Acta Proteins Proteom 1867:879\u2013889","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"83_CR19","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1074\/jbc.M112.403311","volume":"288","author":"U Dettmer","year":"2013","unstructured":"Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D (2013) In vivo cross-linking reveals principally oligomeric forms of \u03b1-synuclein and \u03b2-synuclein in neurons and non-neural cells. J Biol Chem 288:6371\u20136385","journal-title":"J Biol Chem"},{"key":"83_CR20","doi-asserted-by":"publisher","first-page":"9596","DOI":"10.1073\/pnas.1505953112","volume":"112","author":"U Dettmer","year":"2015","unstructured":"Dettmer U, Newman AJ, Saucken VE, von, Bartels T, Selkoe D (2015a) KTKEGV repeat motifs are key mediators of normal \u03b1-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. Proc Natl Acad Sci USA 112:9596\u20139601","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8314","volume":"6","author":"U Dettmer","year":"2015","unstructured":"Dettmer U, Newman AJ, Soldner F, Luth ES, Kim NC, Saucken VE, von, Sanderson JB, Jaenisch R, Bartels T, Selkoe D (2015b) Parkinson-causing \u03b1-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 6:7314","journal-title":"Nat Commun"},{"key":"83_CR22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/nature02261","volume":"426","author":"CM Dobson","year":"2003","unstructured":"Dobson CM (2003) Protein folding and misfolding. Nature 426:884\u2013890","journal-title":"Nature"},{"key":"83_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1096\/fj.03-1449com","volume":"20","author":"OMA El-Agnaf","year":"2006","unstructured":"El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease. FASEB J 20:419\u2013425","journal-title":"FASEB J"},{"key":"83_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","volume":"73","author":"S Fanning","year":"2019","unstructured":"Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, Termine D, Ramalingam N, Ho GPH, Noble T et al (2019) Lipidomic analysis of \u03b1-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment. Mol Cell 73:1001\u20131014.e8","journal-title":"Mol Cell"},{"key":"83_CR25","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet B, Mbefo MK, Fares M-B, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N et al (2012) \u03b1-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287:15345\u201315364","journal-title":"J Biol Chem"},{"key":"83_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jnc.14809","volume":"150","author":"M Fayyad","year":"2019","unstructured":"Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, El-Agnaf OMA (2019) Parkinson\u2019s disease biomarkers based on \u03b1-synuclein. J Neurochem 150:626\u2013636","journal-title":"J Neurochem"},{"key":"83_CR27","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.dib.2018.09.026","volume":"20","author":"RD Fern\u00e1ndez","year":"2018","unstructured":"Fern\u00e1ndez RD, Lucas HR (2018) Mass spectrometry data confirming tetrameric \u03b1-synuclein N-terminal acetylation. Data Brief 20:1686\u20131691","journal-title":"Data Brief"},{"key":"83_CR28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, Cecchi C, Vendruscolo M, Chiti F, Cremades N et al (2017) Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Science 358:1440\u20131443","journal-title":"Science"},{"key":"83_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.702639","volume":"13","author":"U Ganguly","year":"2021","unstructured":"Ganguly U, Singh S, Pal S, Prasad S, Agrawal BK, Saini RV, Chakrabarti S (2021) Alpha-synuclein as a biomarker of Parkinson\u2019s disease: good, but not good enough. Front Aging Neurosci 13:702639","journal-title":"Front Aging Neurosci"},{"key":"83_CR30","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"83_CR31","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.1074\/jbc.C113.538249","volume":"289","author":"N Gould","year":"2014","unstructured":"Gould N, Mor DE, Lightfoot R, Malkus K, Giasson B, Ischiropoulos H (2014) Evidence of native \u03b1-synuclein conformers in the human brain. J Biol Chem 289:7929\u20137934","journal-title":"J Biol Chem"},{"key":"83_CR32","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/jnnp-2023-331083","volume":"94","author":"N Hannaway","year":"2023","unstructured":"Hannaway N, Zarkali A, Leyland L-A, Bremner F, Nicholas JM, Wagner SK, Roig M, Keane PA, Toosy A, Chataway J et al (2023) Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 94:742\u2013750","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"83_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep33928","volume":"6","author":"M Iljina","year":"2016","unstructured":"Iljina M, Tosatto L, Choi ML, Sang JC, Ye Y, Hughes CD, Bryant CE, Gandhi S, Klenerman D (2016) Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein. Sci Rep 6:33928","journal-title":"Sci Rep"},{"key":"83_CR34","doi-asserted-by":"publisher","first-page":"20760","DOI":"10.1073\/pnas.1903216116","volume":"116","author":"T Imberdis","year":"2019","unstructured":"Imberdis T, Negri J, Ramalingam N, Terry-Kantor E, Ho GPH, Fanning S, Stirtz G, Kim T-E, Levy OA, Young-Pearse TL et al (2019) Cell models of lipid-rich \u03b1-synuclein aggregation validate known modifiers of \u03b1-synuclein biology and identify stearoyl-CoA desaturase. Proc Natl Acad Sci USA 116:20760\u201320769","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","volume":"345","author":"R Jakes","year":"1994","unstructured":"Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett 345:27\u201332","journal-title":"FEBS Lett"},{"key":"83_CR36","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.1700465115","volume":"115","author":"S Kim","year":"2018","unstructured":"Kim S, Yun SP, Lee S, Umanah GE, Bandaru VVR, Yin X, Rhee P, Karuppagounder SS, Kwon S-H, Lee H et al (2018) GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers. Proc Natl Acad Sci USA 115:798\u2013803","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/CPJ.0000000000000719","volume":"10","author":"L-A Leyland","year":"2020","unstructured":"Leyland L-A, Bremner FD, Mahmood R, Hewitt S, Durteste M, Cartlidge MRE, Lai MM-M, Miller LE, Saygin AP, Keane PA et al (2020) Visual tests predict dementia risk in Parkinson disease. Neurol Clin Pract 10:29\u201339","journal-title":"Neurol Clin Pract"},{"key":"83_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.parkreldis.2022.09.011","volume":"104","author":"G Liu","year":"2022","unstructured":"Liu G, Yu Z, Gao L, Zheng Y, Feng T (2022) Erythrocytic alpha-synuclein in early Parkinson\u2019s disease: a 3-year longitudinal study. Parkinsonism Relat Disord 104:44\u201348","journal-title":"Parkinsonism Relat Disord"},{"key":"83_CR39","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/mds.28534","volume":"36","author":"H Liu","year":"2021","unstructured":"Liu H, Koros C, Stroh\u00e4ker T, Schulte C, Bozi M, Varvaresos S, Ib\u00e1\u00f1ez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K et al (2021) A novel SNCA A30G mutation causes familial Parkinson\u2019s disease. Mov Disord 36:1624\u20131633","journal-title":"Mov Disord"},{"key":"83_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nn.4529","volume":"20","author":"T Logan","year":"2017","unstructured":"Logan T, Bendor J, Toupin C, Thorn K, Edwards RH (2017) \u03b1-Synuclein promotes dilation of the exocytotic fusion pore. Nat Neurosci 20:681\u2013689","journal-title":"Nat Neurosci"},{"key":"83_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","volume":"8","author":"P Magalh\u00e3es","year":"2022","unstructured":"Magalh\u00e3es P, Lashuel HA (2022) Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson\u2019s disease and other synucleinopathies. NPJ Parkinsons Dis 8:93","journal-title":"NPJ Parkinsons Dis"},{"key":"83_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21027-4","volume":"12","author":"WK Man","year":"2021","unstructured":"Man WK, Tahirbegi B, Vrettas MD, Preet S, Ying L, Vendruscolo M, Simone A, de, Fusco G (2021) The docking of synaptic vesicles on the presynaptic membrane induced by \u03b1-synuclein is modulated by lipid composition. Nat Commun 12:927","journal-title":"Nat Commun"},{"key":"83_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neulet.2005.02.030","volume":"381","author":"AW Michell","year":"2005","unstructured":"Michell AW, Luheshi LM, Barker RA (2005) Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson\u2019s disease. Neurosci Lett 381:294\u2013298","journal-title":"Neurosci Lett"},{"key":"83_CR44","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s13311-022-01199-7","volume":"19","author":"S Nuber","year":"2022","unstructured":"Nuber S, Chung CY, Tardiff DF, Bechade PA, McCaffery TD, Shimanaka K, Choi J, Chang B, Raja W, Neves E et al (2022) A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses \u03b1-Synuclein Toxicity. Neurotherapeutics 19:1018\u20131036","journal-title":"Neurotherapeutics"},{"key":"83_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/ana.25920","volume":"89","author":"S Nuber","year":"2021","unstructured":"Nuber S, Nam AY, Rajsombath MM, Cirka H, Hronowski X, Wang J, Hodgetts K, Kalinichenko LS, M\u00fcller CP, Lambrecht V et al (2021) A stearoyl-coenzyme A desaturase inhibitor prevents multiple Parkinson disease phenotypes in \u03b1-synuclein mice. Ann Neurol 89:74\u201390","journal-title":"Ann Neurol"},{"key":"83_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ajpath.2023.01.010","volume":"193","author":"S Nuber","year":"2023","unstructured":"Nuber S, Selkoe DJ (2023) The Parkinson-associated toxin paraquat shifts physiological \u03b1-synuclein tetramers toward monomers that can be calpain-truncated and form oligomers. Am J Pathol 193:520\u2013531","journal-title":"Am J Pathol"},{"key":"83_CR47","doi-asserted-by":"publisher","first-page":"a024109","DOI":"10.1101\/cshperspect.a024109","volume":"8","author":"RL Nussbaum","year":"2018","unstructured":"Nussbaum RL (2018) Genetics of synucleinopathies. Cold Spring Harb Perspect Med 8:a024109","journal-title":"Cold Spring Harb Perspect Med"},{"key":"83_CR48","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno S-I, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T et al (2023) Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29:1448\u20131455","journal-title":"Nat Med"},{"key":"83_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-8-21","volume":"8","author":"S Papapetropoulos","year":"2008","unstructured":"Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D, Guevara A, Levin B (2008) A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson\u2019s disease. BMC Neurol 8:21","journal-title":"BMC Neurol"},{"key":"83_CR50","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1016\/j.neuron.2023.11.020","volume":"111","author":"LA Parra-Rivas","year":"2023","unstructured":"Parra-Rivas LA, Madhivanan K, Aulston BD, Wang L, Prakashchand DD, Boyer NP, Saia-Cereda VM, Branes-Guerrero K, Pizzo DP, Bagchi P et al (2023) Serine-129 phosphorylation of \u03b1-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function. Neuron 111:4006\u20134023.e10","journal-title":"Neuron"},{"key":"83_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02590","volume":"5","author":"Y Pei","year":"2019","unstructured":"Pei Y, Maitta RW (2019) Alpha synuclein in hematopoiesis and immunity. Heliyon 5:e02590","journal-title":"Heliyon"},{"key":"83_CR52","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1039\/C4AN02306D","volume":"140","author":"AS Phillips","year":"2015","unstructured":"Phillips AS, Gomes AF, Kalapothakis JMD, Gillam JE, Gasparavicius J, Gozzo FC, Kunath T, MacPhee C, Barran PE (2015) Conformational dynamics of \u03b1-synuclein: insights from mass spectrometry. Analyst 140:3070\u20133081","journal-title":"Analyst"},{"key":"83_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.brainres.2012.04.018","volume":"1459","author":"JG Quinn","year":"2012","unstructured":"Quinn JG, Coulson DTR, Brockbank S, Beyer N, Ravid R, Hellemans J, Irvine GB, Johnston JA (2012) \u03b1-Synuclein mRNA and soluble \u03b1-synuclein protein levels in post-mortem brain from patients with Parkinson\u2019s disease, dementia with Lewy bodies, and Alzheimer\u2019s disease. Brain Res 1459:71\u201380","journal-title":"Brain Res"},{"key":"83_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","volume":"9","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam N, Jin S-X, Moors TE, Fonseca-Ornelas L, Shimanaka K, Lei S, Cam HP, Watson AH, Brontesi L, Ding L et al (2023) Dynamic physiological \u03b1-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis 9:4","journal-title":"NPJ Parkinsons Dis"},{"key":"83_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa010","volume":"2","author":"JB Sanderson","year":"2020","unstructured":"Sanderson JB, De S, Jiang H, Rovere M, Jin M, Zaccagnini L, Hays Watson A, de Boni L, Lagomarsino VN, Young-Pearse TL et al (2020) Analysis of \u03b1-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. Brain Commun 2:fcaa010","journal-title":"Brain Commun"},{"key":"83_CR56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000355516","volume":"13","author":"D Selkoe","year":"2014","unstructured":"Selkoe D, Dettmer U, Luth E, Kim N, Newman A, Bartels T (2014) Defining the native state of \u03b1-synuclein. Neurodegener Dis 13:114\u2013117","journal-title":"Neurodegener Dis"},{"key":"83_CR57","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1073\/pnas.97.9.4897","volume":"97","author":"LC Serpell","year":"2000","unstructured":"Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 97:4897\u20134902","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma M, Burr\u00e9 J (2023) \u03b1-Synuclein in synaptic function and dysfunction. Trends Neurosci 46:153\u2013166","journal-title":"Trends Neurosci"},{"key":"83_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14802\/jmd.16061","volume":"10","author":"X Si","year":"2017","unstructured":"Si X, Pu J, Zhang B (2017) Structure, distribution, and genetic profile of \u03b1-synuclein and their potential clinical application in Parkinson\u2019s disease. J Mov Disord 10:69\u201379","journal-title":"J Mov Disord"},{"key":"83_CR60","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417","journal-title":"Lancet Neurol"},{"key":"83_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/BMM.14.105","volume":"10","author":"AH Simonsen","year":"2016","unstructured":"Simonsen AH, Kuiperij B, El-Agnaf OMA, Engelborghs S, Herukka S-K, Parnetti L, Rektorova I, Vanmechelen E, Kapaki E, Verbeek M et al (2016) The utility of \u03b1-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med 10:19\u201334","journal-title":"Biomark Med"},{"key":"83_CR62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00441-022-03595-z","volume":"392","author":"HG Standke","year":"2023","unstructured":"Standke HG, Kraus A (2023) Seed amplification and RT-QuIC assays to investigate protein seed structures and strains. Cell Tissue Res 392:323\u2013335","journal-title":"Cell Tissue Res"},{"key":"83_CR63","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pro.2056","volume":"21","author":"AJ Trexler","year":"2012","unstructured":"Trexler AJ, Rhoades E (2012) N-Terminal acetylation is critical for forming \u03b1-helical oligomer of \u03b1-synuclein. Protein Sci 21:601\u2013605","journal-title":"Protein Sci"},{"key":"83_CR64","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1523\/JNEUROSCI.1881-21.2022","volume":"42","author":"A Tripathi","year":"2022","unstructured":"Tripathi A, Alnakhala H, Terry-Kantor E, Newman A, Liu L, Imberdis T, Fanning S, Nuber S, Ramalingam N, Selkoe D et al (2022) Pathogenic mechanisms of cytosolic and membrane-enriched \u03b1-synuclein converge on fatty acid homeostasis. J Neurosci 42:2116\u20132130","journal-title":"J Neurosci"},{"key":"83_CR65","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1021\/acs.jpcb.2c08326","volume":"127","author":"J Vaneyck","year":"2023","unstructured":"Vaneyck J, Yousif TA, Segers-Nolten I, Blum C, Claessens MMAE (2023) Quantitative seed amplification assay: a proof-of-principle study. J Phys Chem B 127:1735\u20131743","journal-title":"J Phys Chem B"},{"key":"83_CR66","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.1073\/pnas.0712179105","volume":"105","author":"M Vilar","year":"2008","unstructured":"Vilar M, Chou H-T, L\u00fchrs T, Maji SK, Riek-Loher D, Verel R, Manning G, Stahlberg H, Riek R (2008) The fold of alpha-synuclein fibrils. Proc Natl Acad Sci USA 105:8637\u20138642","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR67","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.cub.2014.08.027","volume":"24","author":"L Wang","year":"2014","unstructured":"Wang L, Das U, Scott DA, Tang Y, McLean PJ, Roy S (2014) \u03b1-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol 24:2319\u20132326","journal-title":"Curr Biol"},{"key":"83_CR68","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1073\/pnas.1113260108","volume":"108","author":"W Wang","year":"2011","unstructured":"Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LTT, Liao J, Auclair JR, Johnson D, Landeru A, Simorellis AK et al (2011) A soluble \u03b1-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 108:17797\u201317802","journal-title":"Proc Natl Acad Sci USA"},{"key":"83_CR69","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1074\/jbc.M112.418871","volume":"288","author":"CH Westphal","year":"2013","unstructured":"Westphal CH, Chandra SS (2013) Monomeric synucleins generate membrane curvature. J Biol Chem 288:1829\u20131840","journal-title":"J Biol Chem"},{"key":"83_CR70","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00702-023-02635-4","volume":"130","author":"U W\u00fcllner","year":"2023","unstructured":"W\u00fcllner U, Borghammer P, Choe C-U, Csoti I, Falkenburger B, Gasser T, Lingor P, Riederer P (2023) The heterogeneity of Parkinson\u2019s disease. J Neural Transm 130:827\u2013838","journal-title":"J Neural Transm"},{"key":"83_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135274","volume":"736","author":"W Yang","year":"2020","unstructured":"Yang W, Li X, Li X, Yu S (2020) Hemoglobin-\u03b1-synuclein complex exhibited age-dependent alterations in the human striatum and peripheral RBCs. Neurosci Lett 736:135274","journal-title":"Neurosci Lett"},{"key":"83_CR72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2022.10.007","volume":"104","author":"D Yoo","year":"2022","unstructured":"Yoo D, Bang J-I, Ahn C, Nyaga VN, Kim Y-E, Kang MJ, Ahn T-B (2022) Diagnostic value of \u03b1-synuclein seeding amplification assays in \u03b1-synucleinopathies: A systematic review and meta-analysis. Parkinsonism Relat Disord 104:99\u2013109","journal-title":"Parkinsonism Relat Disord"},{"key":"83_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.827493","volume":"14","author":"Z Yu","year":"2022","unstructured":"Yu Z, Liu G, Li Y, Arkin E, Zheng Y, Feng T (2022) Erythrocytic \u03b1-synuclein species for Parkinson\u2019s disease diagnosis and the correlations with clinical characteristics. Front Aging Neurosci 14:827493","journal-title":"Front Aging Neurosci"},{"key":"83_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136868","volume":"789","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wang S, Li X, Li X, Ran W, Liu C, Tian W, Yu X, Wu C, Li P et al (2022) Hemoglobin-binding \u03b1-synuclein levels in erythrocytes are elevated in patients with multiple system atrophy. Neurosci Lett 789:136868","journal-title":"Neurosci Lett"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00083-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:02:44Z","timestamp":1785859364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00083-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":74,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,15]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00083-5","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UW received consulting fees\/contracting fees from STADA Pharm, Idorsia, Zambon, Abbvie, Bayer, Bial, and Roche. RSW has received speaking honoraria from GE Healthcare and writing honoraria from Britannia. RSW has received fees for consulting for Therakind. TB received consulting\/contracting fees from Jennsen and Arvinas, part of the research was conducted by research funds provided Eisai Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"10"}}